Navigation Links
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
Date:8/11/2011

rities and Exchange Commission on March 31, 2011 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent Pacira Pharmaceutical's views as of the date of this press release. The Company anticipates that subsequent events and development will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing Pacira Pharmaceutical's views as of any date subsequent to the date of this press release.

Contacts:Company Contact:
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3560
or

Investor Contact:
Pure Communications Inc.
Jennifer Beugelmans, 646-596-7473Pacira Pharmaceuticals, Inc.Consolidated Statement of Operations(in thousands, except shares and per share amounts)(unaudited) Three Months

Ended June 30, Six Months
Ended June 30, 2011 2010 2011 2010 Revenues: Supply revenue

$
,469$
,460$
3,185$
4,383 Royalties

8847761,8221,670 Collaborative licensing and development revenue

1,2838192,4931,786 Total revenues

3,6363,0557,5007,839 Operating expenses: Cost of revenues

3,1152,8496,7816,595 Research and development

4,3814,5967,8939,238 Selling, general and administrative

4,6711,2388,4772,254 Total operating expenses

12,1678,68323,15118,087 Loss from operations

(8,531)(5,628)(15,651)(10,248) Other (expense) income: Interest income

37386573 Interest expense

(676)(887)(3,157)(1,499) Royalty interest obligation

429(433)118(605) Other, net

(22)978873 Total other expense, net

(232)(1,185)(2,886)(1,958) Net loss


SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
2. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
3. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
4. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
5. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
6. Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
7. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
8. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
9. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
10. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
11. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
(Date:4/15/2014)... pre-diabetes in the United States have nearly doubled since 1988, ... Public Health, with obesity apparently to blame for the surge. ... has not hit all groups equally, with alarming increases in ... new research reported in the April 15, 2014 issue of ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains why ... why the virus is able to persist in the body ... an estimated 200 million people worldwide, attacks the liver cells, ... ability to fight infection. It does this by altering cells ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... Orange, NJ. April 10, 2014. John DeLuca, PhD, and ... Biogen Idec to study how persons with multiple sclerosis ... Use of Actual Reality to Measure Everyday Life Functional ... this research. Dr. DeLuca is senior VP of Research ...
(Date:4/14/2014)... A new study identifies a molecule that is a ... molecule could be an important target for colorectal cancer treatment ... of microRNA-135b (miR-135b) in two animal models and human tumors ... was led by researchers at The Ohio State University Comprehensive ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2
... an 8-year-old boy,living with epilepsy, and his mother Amy ... Inc., the exclusive sponsor of Canine,Assistants seizure response dogs. ... him to play sports, take,music lessons, and learn Tae ... seizure when his parents are not around is still ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... April 16 Consumer,Watchdog today joined L.A. City ... that health insurer Blue Cross engaged in unfair,business ... patients,after they got sick., The practice -- ... hundreds,of patients who have been left uninsured, uninsurable, ...
... Pa., April 16 Law Offices of ... potential claims against Inverness,Medical Innovations, Inc. ("Inverness ... securities law violations by Inverness Medical and,certain ... Company,s secondary,public offering on or about November ...
... Participating Courtesy of TriWest -, PHOENIX, April ... protect America,s freedoms in Iraq and Afghanistan, Marines,Chris ... injuries diminish,their spirits. Both received prosthetic limbs, returned ... courtesy of TriWest Healthcare Alliance., As members ...
... Help Build Healthy Communities, VICTORVILLE, Calif., April ... the Victorville Earth Day Eco Tote giveaway.,On Tuesday, ... offices will be handing out recyclable Eco Totes ... the Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: